-
1.发明申请USE OF PENICILLIN-BINDING PROTEINS OR POLYNUCLEOTIDES OR ANTIBODIES THEREOF FOR PREVENTING OR TREATING BACTERIAL INFECTIONS 审中-公开使用PENICILLIN结合蛋白或多核苷酸或其抗体来预防或治疗细菌感染公开(公告)号：US20090053237A1
公开(公告)日：2009-02-26
申请号：US11915055
申请日：2006-05-22
申请人： Maria Leticia Zarantonelli , Aude Antignac , Jean-Michel Alonso , Muhamed-Kheir Taha , Faridabano Nato
发明人： Maria Leticia Zarantonelli , Aude Antignac , Jean-Michel Alonso , Muhamed-Kheir Taha , Faridabano Nato
IPC分类号： A61K39/395 , C07K14/00 , C07H21/00 , C07K16/00 , A61P31/04 , A61P37/04 , G01N33/53 , A61K38/16 , A61K39/095
CPC分类号： A61K39/095 , A61K2039/505 , C07K14/22 , C07K16/1217
摘要： The present invention is drawn to a penicillin-binding protein expressed by Neisseria meningitidis, or a fragment, or a variant, or a variant fragment thereof, or nucleic acids encoding them, or antibodies or antibody fragments directed against them, as medicaments or in pharmaceutical compositions. The invention is also directed to the use of penicillin-binding proteins expressed by Neisseria meningitidis, or nucleic acids encoding them, or antibodies directed against them for the prophylactic and/or therapeutic immunotherapy of mammals, preferably human beings, against infection by Neisseria meningitidis and/or by a bacterial strain expressing a variant of a Neisseria meningitidis penicillin-binding protein.
摘要翻译： 本发明涉及由脑膜炎奈瑟氏球菌或其片段，变体或其变体片段或编码它们的核酸，或针对它们的抗体或抗体片段作为药物或药物中表达的青霉素结合蛋白 组合物。 本发明还涉及脑膜炎奈瑟菌脑膜炎奈瑟氏球菌表达的青霉素结合蛋白或编码它们的核酸，或针对它们的抗体用于预防和/或治疗哺乳动物，优选人类免疫治疗，用于脑膜炎奈瑟氏球菌感染和 /或通过表达脑膜炎奈瑟氏球菌青霉素结合蛋白的变体的细菌菌株。
-
2.发明授权Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use 失效重组恶性疟原虫裂殖子表面蛋白4和5及其用途公开(公告)号：US08026354B2
公开(公告)日：2011-09-27
申请号：US11603310
申请日：2006-11-22
CPC分类号： C07K14/445 , A61K39/00 , A61K39/015 , A61K2039/505 , C07K16/205 , C12N2799/026 , G01N33/6893 , Y02A50/412
摘要： Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.
摘要翻译： 因此，本发明提供了编码恶性疟原虫MSP4和MSP5的核酸以及所得多肽已被修饰的构建体。 更具体地，本发明提供编码重组MSP4和MSP5多肽的构建体，其在杆状病毒 - 昆虫细胞表达系统中表达为可溶性分泌的多肽。 惊奇地发现重组多肽在C末端含有适当折叠在多肽中的EGF样结构域。
-
3.发明申请IMMUNOVECTORS WHICH CAN BE USED FOR THE INTRACELLULAR AND INTRANUCLEAR TRANSPORT 审中-公开可用于细胞内和体内运输的免疫球蛋白公开(公告)号：US20110020928A1
公开(公告)日：2011-01-27
申请号：US12899170
申请日：2010-10-06
CPC分类号： C07K16/18 , A61K47/6845 , A61K48/00
摘要： A method of transferring a biologically active principle of interest into a cell by coupling an antibody or a fragment of an antibody, which recognizes an epitope contained in a nucleic acid, with the biologically active principle, to form a coupled biologically active principle; and incubating the coupled biologically active principle, which is transferred through the cell membrane and into the cell, with the cell.
摘要翻译： 通过将识别核酸中包含的表位的抗体或抗体片段与生物学活性原子偶联以形成偶联的生物学活性原理，将感兴趣的生物活性原理转移到细胞中的方法; 并通过细胞孵育通过细胞膜转移到细胞中的偶联生物活性原理。
-
4.发明申请PURIFIED POLYPEPTIDE COMPRISING OR CONSISTING OF A C-TERMINUS MSP1 ANTIGEN FROM PLASMODIUM FALCIPARUM CARRYING A GLYCOSYL-PHOSPHATIDYL-INOSITOL GROUP (GPI) 失效包含或包含来自携带糖蛋白 - 磷脂酰胺基团（GPI）的丙酸纤维素的C-TERMINUS MSP1抗原的纯化多肽公开(公告)号：US20100255038A1
公开(公告)日：2010-10-07
申请号：US11622845
申请日：2007-01-12
IPC分类号： A61K39/015 , C07H21/04 , C07K14/445 , C07K7/00 , A61P31/12 , C12N15/63 , C12N7/01
CPC分类号： A61K39/015 , A01K2227/101 , A01K2267/02 , A61K39/00 , C07K14/445 , C07K16/205 , C12N2799/026 , Y02A50/412
摘要： The present invention relates to a purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI), an immunogenic composition and a vaccine against a Plasmodium infection comprising said purified polypeptide.
摘要翻译： 本发明涉及包含携带糖基 - 磷脂酰肌醇基团（GPI）的恶性疟原虫的C末端MSP1抗原或免疫原性组合物和针对包含所述纯化多肽的疟原虫感染疫苗的纯化多肽。
-
公开(公告)号：US06608034B1
公开(公告)日：2003-08-19
申请号：US08981474
申请日：1998-04-28
IPC分类号： A61K3170
CPC分类号： C07K16/18 , A61K47/6845 , A61K48/00
摘要： A product for coupling a biologically active principle with an immunovector, characterized in that the immunovector is capable of enabling the biologically active principle to be internalized into eukaryotic cells, and in that said immunovector has an affinity for the cell DNA to such an extent that it can transfer the biologically active principle into or to the immediate vicinity of the cell nuclei.
摘要翻译： 用于将生物活性原理与免疫移动体偶联的产物，其特征在于所述免疫移动体能够使所述生物活性原理内化为真核细胞，并且所述免疫移动体对细胞DNA具有亲和力， 可以将生物活性原子转移到细胞核附近或附近。
-
公开(公告)号：US08378087B2
公开(公告)日：2013-02-19
申请号：US13051065
申请日：2011-03-18
CPC分类号： C07K14/445 , A61K39/00 , A61K39/015 , A61K2039/505 , C07K16/205 , C12N2799/026 , G01N33/6893 , Y02A50/412
摘要： Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.
-
7.发明授权Purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI) 失效包含携带糖基 - 磷脂酰肌醇基团（GPI）的来自恶性疟原虫的C末端MSP1抗原或由其构成的纯化多肽公开(公告)号：US08188213B2
公开(公告)日：2012-05-29
申请号：US11622845
申请日：2007-01-12
CPC分类号： A61K39/015 , A01K2227/101 , A01K2267/02 , A61K39/00 , C07K14/445 , C07K16/205 , C12N2799/026 , Y02A50/412
摘要： The present invention relates to a purified polypeptide comprising or consisting of a C-terminus Merozoite Surface Protein 1 (MSP1) antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI), an immunogenic composition and a vaccine against a Plasmodium infection comprising said purified polypeptide.
摘要翻译： 本发明涉及包含携带糖基 - 磷脂酰肌醇基团（GPI）的恶性疟原虫的C末端裂殖子表面蛋白1（MSP1）抗原，免疫原性组合物和抗疟原虫感染的疫苗的纯化多肽，其包含 所述纯化的多肽。
-
8.发明授权公开(公告)号：US06958235B1
公开(公告)日：2005-10-25
申请号：US09125031
申请日：1997-02-14
IPC分类号： G01N33/569 , A61K39/00 , A61K39/015 , A61P33/06 , C07K14/445 , C07K16/18 , C07K16/20 , C12N5/10 , C12N5/24 , C12N15/09 , C12N15/30 , C12N15/86 , C12P21/02 , C12P21/08 , C12R1/01 , C12R1/91 , G01N33/577 , C07H21/04 , C12P21/04
CPC分类号： A61K39/015 , A61K39/00 , C07K14/445 , C07K16/205 , C12N2799/026 , Y02A50/412
摘要： The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.
摘要翻译： 本发明涉及在杆状病毒系统中制备的重组蛋白质，其中必需组成型多肽序列是裂殖子虫寄生虫的表面蛋白1（蛋白质MSP-1）的19千道尔顿（p19）的C末端片段 疟原虫类型，特别是对人感染的恶性疟原虫，说在发生感染性循环时，C末端片段通常在其穿透期结束时在寄生虫的表面锚定在人红细胞中。 所述重组蛋白适用于生产针对疟疾的疫苗。
-
9.发明申请RECOMBINANT PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEINS 4 AND 5 AND THEIR USE 失效重组PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEINS 4 AND 5 AND THEE USE公开(公告)号：US20120115156A1
公开(公告)日：2012-05-10
申请号：US13051065
申请日：2011-03-18
IPC分类号： C12Q1/68 , C12N15/63 , C12N5/10 , C12N15/30 , C12N1/15 , C12N1/19 , C12P21/02 , C07H21/04 , C12N1/21
CPC分类号： C07K14/445 , A61K39/00 , A61K39/015 , A61K2039/505 , C07K16/205 , C12N2799/026 , G01N33/6893 , Y02A50/412
摘要： Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.
摘要翻译： 因此，本发明提供了编码恶性疟原虫MSP4和MSP5的核酸以及所得多肽已被修饰的构建体。 更具体地，本发明提供编码重组MSP4和MSP5多肽的构建体，其在杆状病毒 - 昆虫细胞表达系统中表达为可溶性分泌的多肽。 惊奇地发现重组多肽在C末端含有适当折叠在多肽中的EGF样结构域。
-
10.发明授权公开(公告)号：US07696308B2
公开(公告)日：2010-04-13
申请号：US11144833
申请日：2005-06-06
CPC分类号： A61K39/015 , A61K39/00 , C07K14/445 , C07K16/205 , C12N2799/026 , Y02A50/412
摘要： The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.
摘要翻译： 本发明涉及在杆状病毒系统中制备的重组蛋白质，其中必需组成型多肽序列是裂殖子虫寄生虫的表面蛋白1（蛋白质MSP-1）的19千道尔顿（p19）的C末端片段 疟原虫类型，特别是对人感染的恶性疟原虫，说在发生感染性循环时，C末端片段通常在其穿透期结束时在寄生虫的表面锚定在人红细胞中。 所述重组蛋白适用于生产针对疟疾的疫苗。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.025 秒)
